Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2026 Jan;13(1):154-172.
doi: 10.1002/mdc3.70239. Epub 2025 Jul 24.

Profile of People With Parkinson's Disease Treated With a Device-Aided Therapy in Spain. A Comparative Multicenter Observational Study

Diego Santos-García  1   2   3   4 , Ángela Solleiro  2 , Guillermo González-Ortega  5 , Pablo Mir  6   7   8 , Nuria López-Ariztegui  9 , Rocío García Ramos  10 , Inés Legarda  11 , Anna Planas-Ballvé  12 , Deborah Alonso-Modino  13 , Pilar Sánchez-Alonso  14 , Iria Cabo  15 , Marta Blázquez-Estrada  16 , Álvaro Sánchez-Ferro  7   17 ; DATs‐PD GETM Spanish Registry Group
Collaborators, Affiliations
Observational Study

Profile of People With Parkinson's Disease Treated With a Device-Aided Therapy in Spain. A Comparative Multicenter Observational Study

Diego Santos-García et al. Mov Disord Clin Pract. 2026 Jan.

Abstract

Background and objective: New device-aided therapies (DATs) have emerged to treat people with Parkinson's disease (PwP). Our aim was to know which DATs were indicated by the neurologist and to compare the characteristics of the patients treated under real clinical practice in Spain in the year 2024.

Patients and methods: Data collected in the DATs-PD GETM Spanish Registry were used (REDCap). This is a descriptive, observational, prospective, multicenter, clinical registry with progressive inclusion of PwP treated with a DAT in daily clinical practice conditions in more than 40 centers from Spain for 10 years. For this proposal, only data from visit V1 (indication of DAT) were analyzed, but no follow-up data. All patients with information on DAT received until 31/DEC/2024 were included.

Results: A total of 313 PD patients (66.7 ± 9.6 years old at V2; 61.7% males) were treated with a DAT. The most frequent DAT was subcutaneous foslevodopa/foscarbidopa (fLD/fCD) (47%) followed by deep brain stimulation (DBS) (20.1%) and continuous subcutaneous apomorphine infusion (CSAI) (19.8%). Up to 23.6% had received at least one previous DAT and 47% an on-demand therapy. Differences in age, time with fluctuations and other aspects (motor status, quality of life or activities of daily living among others) were observed between different DAT groups. Specifically, patients treated with DBS were younger and had less advanced disease, whereas those who received LECIG were the most affected.

Conclusion: Subcutaneous therapies and DBS were the most frequent DATs (86.9%) implemented in Spain in 2024. Profile differences were detected between DAT types.

Keywords: Parkinson's disease; deep brain stimulation; device‐aided therapies; infusion; registry; subcutaneous.

PubMed Disclaimer

Conflict of interest statement

Ethical Compliance Statement: The project is being conducted in accordance with the ICH Good Clinical Practice version 6 Revision 2 standard, the fundamental ethical principles established in the Declaration of Helsinki and the Oviedo Convention, as well as the Spanish legal requirements for biomedical research (Biomedical Research Law 14/2007). The Project has been approved on 02/APR/2024 by the IRB “Comité de Ética de la Investigación Clínica de Galicia from Spain” with code number 2024/109. Written informed consents from all participants in this study will be obtained. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this work is consistent with those guidelines. The protocol, statistical analysis plan and unidentified participant data will be available on request.

Funding Sources and Conflicts of Interest: The authors declare that there are no funding sources or conflicts of interest relevant to this work. We received grants from the “Fundación Professor Novoa Santos” as a result of the “CONVOCATORIA DE AYUDAS PARA LA REALIZACIÓN DE PROYECTOS DE INVESTIGACIÓN PARA GRUPOS EMERGENTES Y ASOCIADOS DEL INIBIC (2023/2024)”.

Financial Disclosures for the Previous 12 Months: DS‐G has received honoraria for educational presentations and advice service by Abbvie, UCB Pharma, Lundbeck, KRKA, Zambon, Bial, Italfarmaco, Teva, Archímedes, Esteve, Stada, Merz, and grants from the “Fundación Professor Novoa Santos” as a result of the “CONVOCATORIA DE AYUDAS PARA LA REALIZACIÓN DE PROYECTOS DE INVESTIGACIÓN PARA GRUPOS EMERGENTES Y ASOCIADOS DEL INIBIC (2023/2024)”. ÁS has nothing to report. GG‐O has received honoraria for educational purposes from ABBIE, Zambon, Bial, Esteve and Italfarmaco. PM has received financial support from the Spanish Ministry of Science and Innovation (RTC2019‐007150‐1), the Instituto de Salud Carlos III‐Fondo Europeo de Desarrollo Regional (ISCIII‐FEDER) (PI16/01575, PI18/01898, PI19/01576, PI20/00613, PI21/01875, PI22/01704, PI23/00512), the Consejería de Economía, Innovación, Ciencia y Empleo de la Junta de Andalucía (CVI‐02526, CTS‐7685), the Consejería de Salud y Bienestar Social de la Junta de Andalucía (PI‐0471‐2013, PE‐0210‐2018, PI‐0459‐2018, PE‐0186‐2019), the Consejería de Transformación Económica, Industria, Conocimiento y Universidades de la Junta de Andalucía (PY20_00896), and support for attending meetings and/or travel or honorarium for lecturing from Abbott, Allergan, Abbvie, Bial, Britannia, Italfarmaco, Merz, UCB, Teva and Zambon. NL‐A has received honoraria for educational presentations and advice service or travel grants by Abbvie, Italfarmaco, Stada, Lundbeck, UCB, Esteve, Abbott, Zambon, and Bial. RG‐R has received honoraria and grants for lecturing, advisory services from Abbvie, Zambón, Bial, Merk, Stada. IL has received honoraria for educational presentations and advice service by Abbvie, UCB Pharma, Zambon, Bial, and Teva. AP‐B has nothing to report. DA‐M has nothing to report. None. PS‐A has received honoraria for educational presentations and advice service by Abbvie, UCB Pharma, Lundbeck, KRKA, Zambon, Bial, and Teva. IC has received honoraria for educational presentations and advice service by Abbvie, Zambon, Bial, Orion, Italfarmaco and Esteve. MB‐E has received honoraria for educational presentations by Dysport, Esteve, Bial, Italfármaco, Boston Sc. and Stada and for advice service by Esteve, Bial, Suazio. ÁS‐F has received grants or contracts from ERA‐NET Horizon 2020 program JPCOFUND2 (reference number HESOCARE‐329‐073), MDS (eDiary project) and Instituto de Salud Carlos III (reference number P122/01177), consulting fees from Abbvie, Esteve, Orion Pharma, and Prim, and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Abbvie, Bayer, Esteve, MDS Society, EAN, Novartis, Monitor, Organon, Roche, SEN, Stada, Teva, and Zambon.

References

    1. Bloem BR, Okun MS, Klein C. Parkinson's disease. Lancet 2021;397:2284–2303. - PubMed
    1. Tanner CM, Ostrem JL. Parkinson's disease. N Engl J Med 2024;391:442–452. - PubMed
    1. Hauser RA, McDermott MP, Messing S. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. Arch Neurol 2006;63:1756–1760. - PubMed
    1. Foltynie T, Bruno V, Fox S, Kühn AA, Lindop F, Lees AJ. Medical, surgical, and physical treatments for Parkinson's disease. Lancet 2024;403:305–324. - PubMed
    1. Deuschl G, Antonini A, Costa J, et al. European academy of neurology/Movement Disorder Society‐European section guideline on the treatment of Parkinson's disease: I. Invasive therapies. Mov Disord 2022;37:1360–1374. - PubMed

Substances

LinkOut - more resources